PURSUANT TO 18 U.S.C. SECTION 1350,
ADOPTED PURSUANT TO
906 OF THE SARBANES-OXLEY ACT OF 2002
connection with the Quarterly Report on Form 10-Q of Monopar
Therapeutics Inc. (the Company) for the three months ended March
31, 2020, as filed with the Securities and Exchange Commission on
the date hereof (the Report), we, Chandler D. Robinson, and Kim R.
Tsuchimoto, hereby certify, pursuant to 18 U.S.C. §1350, as
adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002,
fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and
information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
/s/ Chandler D.
/s/ Kim R.
This certification accompanies the Form 10-Q to which it relates,
is not deemed filed with the Securities and Exchange Commission and
is not to be incorporated by reference into any filing of Monopar
Therapeutics Inc. under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended (whether made
before or after the date of the Form 10-Q), irrespective of any
general incorporation language contained in such